Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Thomas Jefferson University
University of California, San Francisco
Massachusetts General Hospital
Northwestern University